Use of Intravenous Amiodarone in the Treatment of Nifekalant-Resistant Arrhythmia: A Review of 11 Consecutive Cases with Severe Heart Failure
Authors:
- Koji NakagawaKNKoji Nakagawa
- Kazufumi NakamuraKazufumi Nakamura
- Satoshi NagaseSNSatoshi Nagase
- Takeshi TadaTTTakeshi Tada
- Masato MurakamiMMMasato Murakami
- Yoshiki HataYHYoshiki Hata
- Hiroshi MoritaHMHiroshi Morita
- Kunihisa KohnoKKKunihisa Kohno
- Kazumasa HinaKHKazumasa Hina
- Tohru UjihiraTUTohru Ujihira
- Tohru OheTOTohru Ohe
Open Access
- 31 May 2011
- journal article
- research article
- Published by MDPI AG in Pharmaceuticals
- Vol. 4 (6) , 794-803
Abstract
Background: Both nifekalant hydrochloride (NIF), a selective IKr blocker, and intravenous amiodarone (AMD), a multi-channel (including IKr blocking) blocker, have been reported to be efficacious for refractory arrhythmias. However, the optimal use of those antiarrhythmic drugs for refractory arrhythmia with severe heart failure has not been established. Intravenous AMD might be effective for arrhythmias refractory to NIF in patients with severe heart failure. Here, we report that intravenous amiodarone was effective in the treatment of nifekalant-resistant in a group of arrhythmia patients with severe heart failure. Methods: Eleven severe heart failure patients who had received intravenous AMD for treatment of NIF-resistant arrhythmias were included in this study, and retrospective analysis was performed. Clinical efficacy (terminative and preventive effects on arrhythmia) of intravenous AMD was evaluated. Results: All cases were emergent cases and had depressed left ventricular ejection fraction (30 ± 13%). Clinical arrhythmias were ventricular fibrillation (VF) in four patients, ventricular tachycardia (VT) in six patients, and atrial fibrillation (AF) in one patient. NIF was administered to all patients by intravenous injection. After administration of NIF, VT/VF/AF was terminated in seven of the 10 patients, but a preventive effect was not obtained in any of the patients (NIF-resistance). Intravenous AMD (maintenance dose: 484 ± 166 mg/day) was effective both in termination (80%) and in prevention (80%) of VT/VF events in those patients. It was also effective in termination (80%) and prevention (60%) of AF events refractory to NIF. During continuous AMD administration, no significant adverse effects or proarrhythmic effects were observed in any of the patients. Five patients died within one month, but there was no arrhythmic deaths. Conclusions: Intravenous AMD was effective in NIF-resistant lethal arrhythmias and was relatively safe in emergent cases with severe heart failure.Keywords
This publication has 12 references indexed in Scilit:
- Effects of Intravenous Nifekalant as a Lifesaving Drug for Severe Ventricular Tachyarrhythmias Complicating Acute Coronary SyndromeCirculation Journal, 2009
- Comparison of Nifekalant and Lidocaine for the Treatment of Shock-Refractory Ventricular FibrillationCirculation Journal, 2006
- Can Nifekalant Hydrochloride be Used as a First-Line Drug for Cardiopulmonary Arrest (CPA)?Circulation Journal, 2006
- Nifekalant Hydrochloride Suppresses Severe Electrical Storm in Patients With Malignant Ventricular TachyarrhythmiasCirculation Journal, 2005
- Emergency Treatment With Nifekalant, a Novel Class III Anti-Arrhythmic Agent, for Life-Threatening Refractory Ventricular Tachyarrhythmias Post-Marketing Special InvestigationCirculation Journal, 2005
- Amiodarone as Compared with Lidocaine for Shock-Resistant Ventricular FibrillationNew England Journal of Medicine, 2002
- Amiodarone for Resuscitation after Out-of-Hospital Cardiac Arrest Due to Ventricular FibrillationNew England Journal of Medicine, 1999
- Cellular electropharmacology of amiodaroneCardiovascular Research, 1997
- Effects of MS-551, a New Class III Antiarrhythmic Drug, on Programmed Stimulation-Induced Ventricular Arrhythmias, Electrophysiology, and Hemodynamics in a Canine Myocardial Infarction ModelJournal of Cardiovascular Pharmacology, 1994
- Effects of MS‐551, a new class III antiarrhythmic drug, on action potential and membrane currents in rabbit ventricular myocytesBritish Journal of Pharmacology, 1993